Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness

Prostate

Volumn 73, Issue 10, 2013, Pages 1103-1114

  Mathieu, Romain ^a,b   Evrard, Bertrand ^a   Fromont, Gaëlle ^c,d   Rioux Leclercq, Nathalie ^a   Godet, Julie ^c   Cathelineau, Xavier ^e   Guillé, François ^b,f   Primig, Michael ^a   Chalmel, Frédéric ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d CeRePP Group   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

Author keywords

biomarker; Cancer Testis genes; castration resistant prostate cancer; NR6A1; nuclear receptor

Indexed keywords

NUCLEAR RECEPTOR NR6A1;

AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HORMONAL CARCINOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN EXPRESSION; RNA TRANSCRIPTION; TISSUE MICROARRAY;

AGED; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR RECEPTOR SUBFAMILY 6, GROUP A, MEMBER 1; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS; TESTIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878454822     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22659     Document Type: Article

References (72)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46 (4): 765-781.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004; 172 (3): 910-914.
4. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO,. Natural history of early, localized prostate cancer. JAMA 2004; 291 (22): 2713-2719.
5. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294 (2): 238-244.
6. Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, Li P, Niu X, Feng N, Zhang L, Hua L, Wang Z, Chen M,. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 2012; 72 (11): 1171-1178.
7. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T,. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 (5038): 1643-1647.
8. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Marie Nicolay HJ, Sigalotti L, Maio M,. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol Oncol 2011; 5 (2): 164-182.
9. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, et al. CTdatabase: A knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37 (database issue): D816-D819.
10. Tyagi P, Mirakhur B,. MAGRIT: The largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10 (5): 371-374.
11. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S,. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008; 105 (5): 1650-1655.
12. Caballero OL, Chen YT,. Cancer/Testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 2009; 100 (11): 2014-2021.
13. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ,. Cancer/Testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5 (8): 615-625.
14. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, et al. Prognostic impact of Cancer/Testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008; 8: 2.
15. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 2009; 106 (32): 13493-13498.
16. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11 (22): 8055-8062.
17. Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, Rughetti A, Muzii L, Nuti M, Benedetti Panici P,. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008; 198 (1): 99 e91-e97.
18. Svobodova S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R, Thompson JF, Deb S, Azad A, Davis ID, et al. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer 2011; 47 (3): 460-469.
19. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, Zavilevich K, Albukh T, Christos P, Mazumdar M, et al. Expression of the Cancer/Testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 2007; 7: 11.
20. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P,. Expression of Cancer/Testis antigens in prostate cancer is associated with disease progression. Prostate 2010; 70 (16): 1778-1787.
21. Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH,. Cancer/Testis antigens and urological malignancies. Nat Rev Urol 2012; 9 (7): 386-396.
22. Shiraishi T, Getzenberg RH, Kulkarni P,. Cancer/Testis antigens: Novel tools for discerning aggressive and non-aggressive prostate cancer. Asian J Androl 2012; 14 (3): 400-404.
23. Axelsen JB, Lotem J, Sachs L, Domany E,. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci USA 2007; 104 (32): 13122-13127.
24. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH,. Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 2011; 9: 153.
25. Chalmel F, Rolland AD, Niederhauser-Wiederkehr C, Chung SS, Demougin P, Gattiker A, Moore J, Patard JJ, Wolgemuth DJ, Jegou B, et al. The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci USA 2007; 104 (20): 8346-8351.
26. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, et al. NCBI GEO archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011; 39 (database issue): D1005-D1010.
27. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, Emam I, Farne A, Hastings E, Holloway E, et al. ArrayExpress update-An archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res 2011; 39 (database issue): D1002-D1004.
28. Chung AC, Cooney AJ,. Germ cell nuclear factor. Int J Biochem Cell Biol 2001; 33 (12): 1141-1146.
29. Chung AC, Xu X, Niederreither KA, Cooney AJ,. Loss of orphan nuclear receptor GCNF function disrupts forebrain development and the establishment of the isthmic organizer. Dev Biol 2006; 293 (1): 13-24.
30. Hummelke GC, Cooney AJ,. Reciprocal regulation of the mouse protamine genes by the orphan nuclear receptor germ cell nuclear factor and CREMtau. Mol Reprod Dev 2004; 68 (4): 394-407.
31. Lan ZJ, Gu P, Xu X, Jackson KJ, DeMayo FJ, O'Malley BW, Cooney AJ,. GCNF-dependent repression of BMP-15 and GDF-9 mediates gamete regulation of female fertility. EMBO J 2003; 22 (16): 4070-4081.
32. Rajkovic M, Iwen KA, Hofmann PJ, Harneit A, Weitzel JM,. Functional cooperation between CREM and GCNF directs gene expression in haploid male germ cells. Nucleic Acids Res 2010; 38 (7): 2268-2278.
33. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8 (5): 393-406.
34. Chalmel F, Primig M,. The Annotation, Mapping, Expression and Network (AMEN) suite of tools for molecular systems biology. BMC Bioinformatics 2008; 9: 86.
35. Fromont G, Rozet F, Cathelineau X, Ouzzane A, Doucet L, Fournier G, Cussenot O,. BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy. Prostate 2012; 72 (12): 1359-1365.
36. Britto R, Sallou O, Collin O, Michaux G, Primig M, Chalmel F,. GPSy: A cross-species gene prioritization system for conserved biological processes-application in male gamete development. Nucleic Acids Res 2012; 40 (web server issue): W458-W465.
37. Adesina AM, Nguyen Y, Guanaratne P, Pulliam J, Lopez-Terrada D, Margolin J, Finegold M,. FOXG1 is overexpressed in hepatoblastoma. Hum Pathol 2007; 38 (3): 400-409.
38. Adesina AM, Nguyen Y, Mehta V, Takei H, Stangeby P, Crabtree S, Chintagumpala M, Gumerlock MK,. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol 2007; 85 (2): 111-122.
39. Chan DW, Liu VW, To RM, Chiu PM, Lee WY, Yao KM, Cheung AN, Ngan HY,. Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer. Br J Cancer 2009; 101 (8): 1433-1443.
40. Kim TH, Jo SW, Lee YS, Kim YJ, Lee SC, Kim WJ, Yun SJ,. Forkhead box O-class 1 and forkhead box G1 as prognostic markers for bladder cancer. J Korean Med Sci 2009; 24 (3): 468-473.
41. Cooney AJ, Hummelke GC, Herman T, Chen F, Jackson KJ,. Germ cell nuclear factor is a response element-specific repressor of transcription. Biochem Biophys Res Commun 1998; 245 (1): 94-100.
42. Heinzer C, Susens U, Schmitz TP, Borgmeyer U,. Retinoids induce differential expression and DNA binding of the mouse germ cell nuclear factor in P19 embryonal carcinoma cells. Biol Chem 1998; 379 (3): 349-359.
43. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9 (2): 166-180.
44. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11 (19 Pt 1): 6823-6834.
45. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP,. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4 (7): 844-847.
46. Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, Gallagher WM,. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics Proteomics 2007; 4 (3): 121-134.
47. Smith HA, Cronk RJ, Lang JM, McNeel DG,. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res 2011; 71 (21): 6785-6795.
48. von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE 2011; 6 (7): e21366.
49. Hirose T, O'Brien DA, Jetten AM,. RTR: A new member of the nuclear receptor superfamily that is highly expressed in murine testis. Gene 1995; 152 (2): 247-251.
50. Katz D, Niederberger C, Slaughter GR, Cooney AJ,. Characterization of germ cell-specific expression of the orphan nuclear receptor, germ cell nuclear factor. Endocrinology 1997; 138 (10): 4364-4372.
51. Zhang YL, Akmal KM, Tsuruta JK, Shang Q, Hirose T, Jetten AM, Kim KH, O'Brien DA,. Expression of germ cell nuclear factor (GCNF/RTR) during spermatogenesis. Mol Reprod Dev 1998; 50 (1): 93-102.
52. Susens U, Aguiluz JB, Evans RM, Borgmeyer U,. The germ cell nuclear factor mGCNF is expressed in the developing nervous system. Dev Neurosci 1997; 19 (5): 410-420.
53. Lan ZJ, Xu X, Chung AC, Cooney AJ,. Extra-germ cell expression of mouse nuclear receptor subfamily 6, group A, member 1 (NR6A1). Biol Reprod 2009; 80 (5): 905-912.
54. Chalmel F, Lardenois A, Evrard B, Mathieu R, Feig C, Demougin P, Gattiker A, Schulze W, Jegou B, Kirchhoff C, Primig M,. Global human tissue profiling and protein network analysis reveals distinct levels of transcriptional germline-specificity and identifies target genes for male infertility. Hum Reprod 2012; 27 (11): 3233-3248.
55. Hummelke GC, Meistrich ML, Cooney AJ,. Mouse protamine genes are candidate targets for the novel orphan nuclear receptor, germ cell nuclear factor. Mol Reprod Dev 1998; 50 (4): 396-405.
56. Borgmeyer U,. Dimeric binding of the mouse germ cell nuclear factor. Eur J Biochem 1997; 244 (1): 120-127.
57. Chen F, Cooney AJ, Wang Y, Law SW, O'Malley BW,. Cloning of a novel orphan receptor (GCNF) expressed during germ cell development. Mol Endocrinol 1994; 8 (10): 1434-1444.
58. Greschik H, Schule R,. Germ cell nuclear factor: An orphan receptor with unexpected properties. J Mol Med (Berl) 1998; 76 (12): 800-810.
59. Greschik H, Wurtz JM, Hublitz P, Kohler F, Moras D, Schule R,. Characterization of the DNA-binding and dimerization properties of the nuclear orphan receptor germ cell nuclear factor. Mol Cell Biol 1999; 19 (1): 690-703.
60. Yan ZH, Medvedev A, Hirose T, Gotoh H, Jetten AM,. Characterization of the response element and DNA binding properties of the nuclear orphan receptor germ cell nuclear factor/retinoid receptor-related testis-associated receptor. J Biol Chem 1997; 272 (16): 10565-10572.
61. Bauer UM, Schneider-Hirsch S, Reinhardt S, Pauly T, Maus A, Wang F, Heiermann R, Rentrop M, Maelicke A,. Neuronal cell nuclear factor-A nuclear receptor possibly involved in the control of neurogenesis and neuronal differentiation. Eur J Biochem 1997; 249 (3): 826-837.
62. Fuhrmann G, Chung AC, Jackson KJ, Hummelke G, Baniahmad A, Sutter J, Sylvester I, Scholer HR, Cooney AJ,. Mouse germline restriction of Oct4 expression by germ cell nuclear factor. Dev Cell 2001; 1 (3): 377-387.
63. Yan Z, Jetten AM,. Characterization of the repressor function of the nuclear orphan receptor retinoid receptor-related testis-associated receptor/germ cell nuclear factor. J Biol Chem 2000; 275 (45): 35077-35085.
64. Yan Z, Kim YS, Jetten AM,. RAP80, a novel nuclear protein that interacts with the retinoid-related testis-associated receptor. J Biol Chem 2002; 277 (35): 32379-32388.
65. Mullen EM, Gu P, Cooney AJ,. Nuclear receptors in regulation of mouse ES cell pluripotency and differentiation. PPAR Res 2007; 2007: 61563.
66. Zechel C,. The germ cell nuclear factor (GCNF). Mol Reprod Dev 2005; 72 (4): 550-5556.
67. Zhao H, Li Z, Cooney AJ, Lan ZJ,. Orphan nuclear receptor function in the ovary. Front Biosci 2007; 12: 3398-3405.
68. Sun Y, Niu J, Huang J,. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1 (2): 148-162.
69. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA,. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000; 42 (4): 274-279.
70. Jiborn T, Bjartell A, Abrahamsson PA,. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998; 51 (4): 585-589.
71. Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo MG, Dogliani N, De Giuli P, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005; 48 (2): 215-221; discussion 221-213.
72. Panchision DM, McKay RD,. The control of neural stem cells by morphogenic signals. Curr Opin Genet Dev 2002; 12 (4): 478-487.